WallStSmart

Polestar Automotive Holding UK PLC Class C-1 ADS (ADW) (PSNYW)vsVertex Pharmaceuticals Inc (VRTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Vertex Pharmaceuticals Inc generates 371% more annual revenue ($12.00B vs $2.55B). VRTX leads profitability with a 32.9% profit margin vs -106.0%. VRTX earns a higher WallStSmart Score of 66/100 (B-).

PSNYW

Avoid

34

out of 100

Grade: F

Growth: 6.7Profit: 2.5Value: 5.0Quality: 5.0

VRTX

Strong Buy

66

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 10.0Quality: 8.0
Piotroski: 3/9Altman Z: 3.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for PSNYW.

VRTXUndervalued (+36.5%)

Margin of Safety

+36.5%

Fair Value

$716.04

Current Price

$454.97

$261.07 discount

UndervaluedFair: $716.04Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

PSNYW1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
26.1%8/10

Revenue surging 26.1% year-over-year

VRTX6 strengths · Avg: 9.5/10
Profit MarginProfitability
32.9%10/10

Keeps 33 of every $100 in revenue as profit

Operating MarginProfitability
39.6%10/10

Strong operational efficiency at 39.6%

Altman Z-ScoreHealth
3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality
$113.95B9/10

Large-cap with strong market position

Return on EquityProfitability
22.5%9/10

Every $100 of equity generates 23 in profit

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

Areas to Watch

PSNYW4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
0.0%3/10

ROE of 0.0% — below average capital efficiency

Free Cash FlowQuality
$-292.84M2/10

Negative free cash flow — burning cash

Profit MarginProfitability
-106.0%1/10

Currently unprofitable

VRTX3 concerns · Avg: 3.7/10
PEG RatioValuation
2.194/10

Expensive relative to growth rate

P/E RatioValuation
29.3x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : PSNYW

The strongest argument for PSNYW centers on Revenue Growth. Revenue growth of 26.1% demonstrates continued momentum.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.

Bear Case : PSNYW

The primary concerns for PSNYW are EPS Growth, Return on Equity, Free Cash Flow.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

PSNYW profiles as a growth stock while VRTX is a mature play — different risk/reward profiles.

PSNYW carries more volatility with a beta of 1.65 — expect wider price swings.

PSNYW is growing revenue faster at 26.1% — sustainability is the question.

VRTX generates stronger free cash flow (349M), providing more financial flexibility.

Bottom Line

VRTX scores higher overall (66/100 vs 34/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)

CONSUMER CYCLICAL · AUTO MANUFACTURERS · USA

Polestar Automotive Holding UK PLC (Ticker: PSNYW) is a leading contender in the electric performance vehicle market, distinguished by its commitment to innovation and sustainability. As a subsidiary of Volvo Cars and Geely, Polestar leverages cutting-edge technology and engineering to create high-performance electric vehicles, exemplified by its flagship model, the Polestar 2, which integrates exceptional design with advanced connectivity features. The company is strategically enhancing its global presence and production capabilities, positioning itself to capitalize on the rapid growth of the electric vehicle sector and play a pivotal role in the transition towards a sustainable automotive future.

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?